SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001072613-18-000476
Filing Date
2018-09-17
Accepted
2018-09-17 15:45:22
Documents
1
Group Members
ALI BEHBAHANIANTHONY A. FLORENCE, JR.CARMEN CHANGDAVID M. MOTTFOREST BASKETTJOSHUA MAKOWERMOHAMAD H. MAKHZOUMINEA 14 GP, LTDNEA 16 GP, LLCNEA PARTNERS 14, L.P.NEA PARTNERS 16, L.P.NEW ENTERPRISE ASSOCIATES 16, L.P.PETER J. BARRISPETER W. SONSINIRAVI VISWA

Document Format Files

Seq Description Document Type Size
1 NEW ENTERPRISE ASSOCIATES 14, L.P. / ADAPTIMMUNE THERAPEUTICS PLC -- SCHEDULE 13 adaptimmune-13d_18249.htm SC 13D 580778
  Complete submission text file 0001072613-18-000476.txt   583007
Mailing Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 410-842-4000
New Enterprise Associates 14, L.P. (Filed by) CIK: 0001544328 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Subject) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-88833 | Film No.: 181073388
SIC: 2836 Biological Products, (No Diagnostic Substances)